Tedisamil: Master switch of nature?

Expert Opinion on Investigational Drugs

Volumn 10, Issue 1, 2001, Pages 129-138

  Doggrell, S A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Cardiovascular; Clinical trials; Potassium channels; Tedisamil

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMAKALIM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CHLORIDE; CHLORIDE CHANNEL; CROMAKALIM; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOFETILIDE; ESMOLOL; GALLOPAMIL; GLUCOSE; INOTROPIC AGENT; LIPID; NITRIC ACID DERIVATIVE; NORADRENALIN; OXYGEN; PINACIDIL; PLASMA PROTEIN; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM ION; SOTALOL; TEDISAMIL; UNINDEXED DRUG; VASODILATOR AGENT;

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRONCHUS OBSTRUCTION; CHANNEL GATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DRUG CONFORMATION; DRUG EFFECT; DRUG HALF LIFE; DRUG PROTEIN BINDING; HEART ATRIUM FLUTTER; HEART ATRIUM MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE WALL; HUMAN; HYPERTENSION; IMPOTENCE; INOTROPISM; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NONHUMAN; POTASSIUM CURRENT; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RAT; VENOCONSTRICTION;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINICAL TRIALS; CYCLOPROPANES; ELECTROCARDIOGRAPHY; HUMANS; ION CHANNELS; MYOCARDIAL CONTRACTION;

EID: 0035191671     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.1.129     Document Type: Article

References (46)

1. Heart rate reduction a mechanism of benefit
2. Cardiovascular profile of KC 8857 in comparison with other cardioselective agents
3. The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers
4. Synthesis, pharmacological characterization and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispodines: Derivatives with specific bradycardic activity
5. Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes
6. Positive inotropic responses to potassium channel blockers
7. + current in rat ventricular myocytes
8. Different inhibition patterns of tedisamil for fast and slowly inactivation transient outward current in rat ventricular myocytes
9. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes
10. + currents in mammalian cardiac and glial cells
11. + channels in adult rat ventricular cells
12. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart
13. Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031 and BRL-32872 on protein kinase-activated chloride current in guinea pig ventricular myocytes
14. + current in single smooth muscle cells of the guinea-pig portal vein
15. + channels in membrane patches from smooth muscle cells of the guinea-pig portal vein
16. + efflux-stimulating and vasorelaxant properties of cromakalim
17. + current blocker
18. Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements
19. Frequency-dependent cardiac electrophysiologic effects of tedisamil: Comparison with quinidine and sotalol
20. Prolongation on monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent
21. + current in rabbit ventricular myocytes
22. Electro-mechanical characterisation of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands
23. + current on human and guinea pig ventricular myocytes
24. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: Considerations of the mechanism of reverse rate-dependent action potential prolongation
25. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo
26. Tedisamil attenuates ventricular fibrillation in a conscious canine model of sudden cardiac death
27. Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestive heart failure due to dilated cardiomyopathy
28. Cardiac electrophysiologic and antiarrhythmic actions of tedisamil
29. Differential atrial versus ventricular activities of class III potassium channel blockers
30. to blockade?
31. Early outward current in rat ventricular cells
32. Comparison of potassium currents in rabbit atrial and ventricular cells
33. Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation
34. Acute toxicity of tedisamil, a new potassium channel blocking drug
35. Tedisamil in a chronic canine model of atrial flutter
36. An interspecies comparison of the bradycardic activities of tedisamil dihydrochloride
37. Cardiac and hemodynamic effects of the selective bradycardic agent KC 8857 during exercise-induced myocardial ischemia
38. Tedisamil (KC 8857) is a new specific bradycardic drug: Does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease
39. KC8857, a new compound with combined bradycardic and positive inotropic effects
40. Tedisamil: Cardiac electrophysiologic and functional effects in guinea pigs
41. 86Rb efflux induced by cromakalim, high potassium and noradrenaline and on mechanical tension in rabbit isolated vascular smooth muscle
42. Differential inhibition by tedisamil (KC 8857) and glibenclamide of the responses to cromakalim and minoxidil sulphate in rat isolated aorta
43. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers
44. Comparison of the potassium channel blocker tedisamil and the beta-adrenoceptor blocker esmolol and the calcium channel antagonist gallopamil in patients with coronary artery disease
45. Potassium channel openers and blockers in coronary artery disease. Comparison to beta-blockers and calcium antagonists
46. Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker